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Purpose of the study
IRIS-KS risk factors are not well known and their identifi-
cation would aid in selection of the best therapeutic
approach for high risk patients. The aim of this study was
to identify risk factors for developing IRIS-KS among HIV
and Human herpesvirus 8 (HHV-8) co-infected patients
receiving cART in Mozambique.
Methods
This study was integrated into a larger prospective obser-
vational study conducted in the Manhiça Health Research
Center, designed to characterize IRIS. The cohort
described in the present study included those participants
in the IRIS cohort with detectable anti-HHV-8 lytic anti-
bodies or with KS at recruitment (n = 69). Plasma HIV
viral load, CD4 and CD8 counts, immune activation,
hepatic and renal function, WBC, RBC and platelet
counts, anti-HHV-8 lytic antibodies and plasma and
PBMC HHV-8 viral load were assessed at the pre-cART
visit and at 4 months after cART initiation. Passive surveil-
lance for potential IRIS-KS cases was performed through-
out the study. A univariate and multivariate hazard
analysis was carried out in order to assess potential risk
factors for developing IRIS-KS among HHV-8 infected
patients.
Summary of results
Thirteen patients presented with KS at the initial pre-cART
visit and four additional patients were diagnosed with KS
after cART initiation. Eight patients out of 69 (11.6%)
experienced either an abrupt clinical worsening (four) or
debuted with KS (four) with a median time of 13.8 weeks
(IQR, 3–23) after cART initiation, in the context of a mean
2.58 log10 copies/mL (sd 0.2) decline in plasma HIV-
RNA viral load and a median increase of 95 CD4+ cells/μl
(IQR, 6–136) from pre-cART levels. Multivariate hazard
analysis showed that, at pre-cART visit, a plasma HIV-RNA
viral load>5 log10 copies/mL, a body mass index
(BMI)<18.5 and the presence of KS were independently
associated with the development of IRIS-KS. At 4 months
after cART, IRIS-KS cases tended to have achieved a better
HIV virologic control and a higher absolute change in
anti-HHV-8 lytic antibodies than those HHV-8 infected
patients that did not develop IRIS-KS. In order to better
characterize the relation between HHV-8 and IRIS-KS,
determination of HHV-8 DNA loads is currently under-
way.
Conclusion
In this cohort of antiretroviral-naïve HIV and HHV-8 co-
infected African patients, IRIS-KS was observed in 11.6%
of patients. A plasma HIV-1 RNA viral load>5 log10 cop-
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ies/mL, a BMI<18.5, and the presence of KS at baseline
were independent predictors of IRIS-KS. Close clinical
supervision is warranted for these patients.
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